Sep. 13 at 4:36 PM
$VKTX Oral approval is a ways away. Not sure it's worth holding the stock for that.
But the subq data is due early 2027. The stock will likely rally *prior* to that, so you probably want to be invested by mid-2026, at the latest, if you're bullish long term.
But perhaps more importantly, some big pharma not currently in the GLP-1 game are likely salivating at the idea of owning these drugs. That means VKTX is an acquisition risk at all times, so not being invested at all times is a big risk.
If you're not patient, maybe try holding a small position for now, and buying more in mid-2026. Nfa.
